Quantcast

For Dyslipidemia Treatment, the Rapid Uptake of Dalcetrapib and Anacetrapib Will Drive $3.2 Billion in Sales of CETP Inhibitors in 2018

January 25, 2010

WALTHAM, Mass., Jan. 25 /PRNewswire/ –Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of dyslipidemia, the rapid uptake of Roche/Japan Tobacco’s first-in-class dalcetrapib and Merck’s anacetrapib will drive $3.2 billion in sales of the cholesteryl ester transfer protein (CETP) inhibitors drug class in 2018 in the world’s major pharmaceutical markets.

Anacetrapib and dalcetrapib appear to be free of the unexpected toxicity that halted the development of Pfizer’s CETP inhibitor torcetrapib in 2006. Once on the market, these newer CETP inhibitors will initially compete with niacin derivatives and niacin combinations for later-line use in patients with mixed dyslipidemia or in patients considered to be at particularly high cardiovascular risk. An advantage for CETP inhibitors is that, unlike niacin derivatives, CETP inhibitors do not cause flushing and do not carry the risk of increasing blood glucose levels, which will significantly widen their appeal with prescribers and patients.

The Pharmacor 2010 finding from the topic entitled Dyslipidemia also reveals that the outcomes of several major ongoing clinical trials, including ACCORD (for Abbott’s Tricor), AIM-HIGH and HPS2-THRIVE (for niacin products) and IMPROVE-IT (for Merck’s Zetia/Ezetrol and Vytorin/Inegy), will result in greater physician consensus regarding dyslipidemia treatment and will trigger changes to international guidelines for the management of the disease.

“Results from HPS2-THRIVE are not expected until 2013, after the findings of AIM-HIGH, which are expected in 2011,” said Decision Resources Director Nikhil Mehta. “The results from both outcomes trials will provide substantial evidence that will influence guidelines and potentially unify clinical practice for or against the use of niacin.”

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.


    Decision Resources                        Decision Resources, Inc.
    Gisselle Morales                          Christopher Comfort
    781-296-2691                              781-296-2597
    gmorales@dresources.com                   ccomfort@dresources.com

SOURCE Decision Resources


Source: newswire



comments powered by Disqus